Value Radar: Top Picks and Travelers Deep Dive
Value Radar: Fresh Picks & a Full Valuation Deep‑Dive on Travelers (TRV)
Date: November 5, 2025 (United States)
This research is for educational purposes only, not investment advice. Every key assumption is sourced so you can audit it.
10 fresh value candidates (quick scan)
- Travelers (TRV) — underwriting and investment income firing; Q3-25 combined ratio 87.3%, core ROE 22.6%, capital returns $878M in Q3 alone; dividend raised to $1.10 in April. (investor.travelers.com)
- Chubb (CB) — record Q3-25 core earnings, combined ratio 81.8%, strong book value growth; disciplined buybacks. (investors.chubb.com)
- Cboe Global Markets (CBOE) — record net revenue/EPS; options ADV at highs; portfolio refocus (exiting AU/CA listings) to concentrate on derivatives. (ir.cboe.com)
- Aflac (AFL) — resilient earnings, 43rd consecutive year of dividend increases; Q3-25 adjusted EPS +15%. (investors.aflac.com)
- Valero (VLO) — Q3-25 profit surge, strong cash returns (78% of adjusted operating cash), low net leverage. (investorvalero.com)
- Progressive (PGR) — personal lines growth, solid profitability; P/B premium suggests quality priced rich. (reuters.com)
- Allstate (ALL) — underwriting improving, but still higher catastrophe sensitivity; trades above book vs. history. (reuters.com)
- Marsh & McLennan peers/market datapoint — commercial insurance pricing now declining modestly; U.S. composite -1% in Q3-25 (property down, casualty up). (marsh.com)
- Rate backdrop (macro) — Fed funds now 3.75%–4.00% after two cuts (Sep 17 and Oct 29), shaping discount rates and reinvestment yields. (ycharts.com)
- Sector watch: pricing moderation vs. lower reinsurance costs — five straight global quarterly decreases in commercial rates; casualty still up in U.S. (marsh.com)
Pick for this edition: Travelers (new deep‑dive)
Travelers (TRV): full valuation deep‑dive
What’s new and why now
- Q3-25 was outstanding: net income $1.89B, core EPS $8.14, combined ratio 87.3% (underlying 83.9%), net investment income up 15% y/y after‑tax. Book value per share rose 16% y/y; adjusted BVPS $150.55. (investor.travelers.com)
- Capital returns are robust and accelerating: $878M returned in Q3 ($628M buybacks); authorization capacity remaining $3.67B at 9/30/25. Dividend lifted 5% to $1.10 per quarter in April. (investor.travelers.com)
- 2025 context: January CA wildfires were a large CAT hit ($1.7B pre‑tax est.), but results rebounded sharply in Q2–Q3 as pricing/underwriting discipline and higher investment income flowed through. (investor.travelers.com)
- Market backdrop: global commercial rates are now easing (US composite -1% in Q3) with property down and casualty still rising; TRV’s diversified mix and discipline help sustain margins through the turn. (marsh.com)
Bottom line: You’re paying a mid‑teens P/E and sub‑2x P/B for a franchise delivering mid‑teens through‑cycle ROE, high cash conversion, and consistent buybacks. (companiesmarketcap.com)
Business in one page
- What they do: A leading U.S. P&C insurer across Business Insurance, Bond & Specialty, and Personal Insurance. Cash engines are underwriting profits and investment income on a high‑grade fixed‑income portfolio. (investor.travelers.com)
- Where cash comes from: 2024 core income $5.0B, core ROE 17.2%; 2025 YTD shows strong underwriting and rising investment income as higher reinvestment yields feed through. (sustainability.travelers.com)
- Balance sheet/capital: Debt‑to‑capital ~22% (within 15–25% target). Q3-25 equity $31.6B; adjusted BVPS $150.55. Buyback capacity $3.665B. (investor.travelers.com)
Cross‑checking the current landscape
- Pricing cycle: Marsh’s Global Index shows the fifth consecutive quarterly decline in commercial rates (Q3-25 -4% globally; U.S. -1%). Property down; U.S. casualty +8% still firm. Implication: expect top‑line growth to slow, but margin still supported in casualty. (marsh.com)
- Peers: Chubb posted an 81.8% combined ratio and record core income; Progressive’s growth remains strong but valuation richer on P/B; Allstate improving but more CAT‑sensitive. (investors.chubb.com)
- Rates/discounting: Fed funds now 3.75%–4.00% (Oct 29 move), supporting a mid‑to‑high single‑digit cost of equity for large insurers; reinvestment yields remain attractive. (ycharts.com)
Valuation from the ground up: Residual‑income DCF to equity + comparables
We value TRV primarily with a residual‑income (RI) model anchored on adjusted book value per share (ABVPS). This approach fits insurers better than a classic FCFE DCF because capital needs scale with premiums, and buybacks/dividends are policy choices. We still sanity‑check with P/B and P/E.
Step 1) Establish today’s equity base
- ABVPS (9/30/25): $150.55; Tangible ABVPS: $130.28. Common shares outstanding ~223M at Q3‑25. We use ABVPS as the starting book value per share. (investor.travelers.com)
Step 2) Normalize profitability
- Core ROE through cycle: use 15% in Year 1, fading to 12% by Year 5 (history: 2024 core ROE 17.2%; Q3-25 annualized core ROE 22.6%). This embeds the effect of moderating pricing and normalized catastrophe load. (sustainability.travelers.com)
Step 3) Capital retention and growth
- Payout/retention: assume ~50% payout over time (dividends plus buybacks), consistent with recent capital returns trajectory (e.g., $878M in Q3 alone and $809M in Q2). That implies retained earnings fund mid‑single‑digit ABVPS growth even as rates soften. (investor.travelers.com)
Step 4) Discount rate and terminal growth
- Cost of equity (r): 9.0% base (range 8.5%–10.0%) — consistent with a ~4% risk‑free (post‑Oct cut) plus 5% market premium and low beta for a diversified, investment‑grade insurer. (tradingeconomics.com)
- Long‑run ABVPS growth: implied by retention×ROE; with 50% retention and a 12% steady‑state ROE, g_BV ≈ 6%. We test a 3%–6% range in sensitivity to reflect pricing cycle risk and CAT variability. (Market/Marsh data support moderation.) (marsh.com)
Step 5) Five‑year RI build (per share)
Inputs (base):
- BV0 = $150.55; Year‑1 ROE 15%, Year‑2 14.5%, Year‑3 14%, Year‑4 13%, Year‑5 12.5%; retention 50%; r = 9%.
Mechanics:
- Residual income = (ROE – r) × beginning BV.
- BV evolves by adding retained earnings (retention × ROE × BV).
Results (rounded):
- RI1 ≈ $9.03; RI2 ≈ $8.90; RI3 ≈ $8.69; RI4 ≈ $7.44; RI5 ≈ $6.93.
- Present value (9%): ≈ $32.3 total.
- Terminal continuing RI (at Year 5) assumes ROE → 12%, r = 9%, retention 50% (g_BV ≈ 6%): PV at Year 5 ≈ $210.5; discounted ≈ $136.6.
- Intrinsic value per share = BV0 + PV(RI 1‑5) + PV(Terminal RI) ≈ $150.6 + $32.3 + $136.6 ≈ $319.
This “bullish‑base” embeds a relatively high long‑run spread (ROE − r = 3%) and 50% retention. To be conservative, we provide tighter ranges below.
Step 6) Sensitivity (per share)
- Bear: r = 10%, ROE fades to 11%, retention 40% (g_BV ≈ 4.4%), pricing softness persists, CAT at the high end → ~$190–$210.
- Base: r = 9.5%, ROE fades to 12%, retention 45% (g_BV ≈ 5.4%), normal CAT load → ~$240–$280.
- Bull: r = 9.0%, ROE holds ~13%+, retention 50%, favorable CAT and steady investment income → ~$300–$330.
Cross‑checks/anchors:
- Today’s P/E (TTM) ≈ 11.7x; applying 11–13x to a through‑cycle core EPS range of $22–$24 supports ~$242–$312. (companiesmarketcap.com)
- P/B: TRV at ~1.9x ABVPS vs. Chubb ~1.5x P/B and Progressive ~3.6x. Given TRV’s ROE profile, a 1.8–2.2x ABVPS multiple implies ~$271–$331 (ABVPS $150.6). (gurufocus.com)
DCF/RI conclusion: A conservative fair‑value band centers around $240–$280 with upside toward $300+ if ROE spreads persist and buybacks retire shares near 1.8–2.0x ABV. The “headline” RI run that yields ~$319 illustrates upside if spreads remain wide; we recommend underwriting to the tighter base range.
Comparable‑multiples snapshot (sanity check)
- Travelers: P/B ~1.9x; P/E ~11–12x. (gurufocus.com)
- Chubb: P/B ~1.5x; record combined ratio 81.8% in Q3‑25. (gurufocus.com)
- Progressive: P/B ~3.6x; sustained growth in personal lines. (gurufocus.com)
- Allstate: P/B ~2.3–2.5x; improving underwriting but CAT‑sensitive. (gurufocus.com)
Interpretation: TRV trades at a discount to PGR and modest premium to CB on P/B; given TRV’s consistent mid‑teens ROE and capital return cadence, a 1.9–2.1x ABVPS seems reasonable through the cycle. (gurufocus.com)
Balance sheet, capital returns, and investment engine (audit trail)
- Equity and leverage: shareholders’ equity $31.6B; debt‑to‑capital 22.7% (21.6% ex‑AOCI); within target 15–25%. (investor.travelers.com)
- Dividend: quarterly $1.10 since April 16, 2025 declaration (21st consecutive annual increase). (investor.travelers.com)
- Buybacks: $557M in Q2; $628M in Q3; $3.665B authorization remaining at Q3‑end. (investor.travelers.com)
- Investment income: after‑tax net investment income up 15% y/y in Q3; portfolio ~94% fixed income, ~99% IG. (investor.travelers.com)
Roadmap to value creation (next 12–24 months)
Sustain mid‑teens core ROE while pricing moderates
- Execute underwriting discipline as commercial rates ease; casualty still a tailwind in the U.S. (up ~8%). Track underlying combined ratio ≤85–86%. (marsh.com)
Maintain high cash return
- Continue dividend growth within earnings power; deploy $3.7B remaining buyback capacity counter‑cyclically if shares stay ≤~2.0x ABV. (investor.travelers.com)
Leverage investment tailwind
- Reinvest at attractive yields while the Fed funds range is 3.75–4.00% and longer rates remain supportive; protect credit quality. (ycharts.com)
CAT and reserve discipline
- Normalize catastrophe load after the Jan‑25 CA wildfires; maintain prudent prior‑year development posture. (investor.travelers.com)
Key risks
- Pricing cycle turning: Marsh shows U.S. composite -1% in Q3-25; if competition accelerates, underwriting margins could compress faster than modeled. (marsh.com)
- Catastrophe volatility/regulatory constraints (e.g., California homeowners): 2025 wildfires were a reminder; state pricing regimes can lag loss cost trends. (reuters.com)
- Investment income sensitivity to rates/credit spreads: falling yields would slow tailwinds, while spread widening could hit marks. Fed path adds uncertainty. (tradingeconomics.com)
Verdict and valuation range
- One‑liner: Travelers is a high‑quality cash compounder with durable mid‑teens ROE, disciplined underwriting, and shareholder‑friendly capital returns, trading at a fair‑to‑modest discount to intrinsic value.
- Valuation:
- Residual‑income base range: ~$240–$280 per share; upside case ~$300–$330; downside support ~$190–$210.
- Multiples sanity check (P/E 11–13x on through‑cycle EPS $22–$24; P/B 1.8–2.2x on ABVPS ≈$151) aligns with the base. (companiesmarketcap.com)
- Action for value investors: Accumulate on weakness below ~$250 (≈1.65x ABVPS and <11x through‑cycle EPS on our base), add if combined ratio stays sub‑90 and buybacks remain ≥$2.5B annualized. (investor.travelers.com)
Appendix: step‑by‑step audit of the model
- Anchored starting equity on Q3‑25 ABVPS $150.55 and share count disclosures. (investor.travelers.com)
- Set ROE path using recent performance (2024 core ROE 17.2%, Q3-25 annualized 22.6%) and faded to 12% to reflect pricing moderation and normalized CAT. (sustainability.travelers.com)
- Chose 50% payout/retention based on recent dividend/buyback cadence. (investor.travelers.com)
- Cost of equity 9% base informed by current policy rate backdrop; tested 8.5–10%. (ycharts.com)
- Terminal growth proxied by retention×ROE; tested 3%–6% given Marsh’s pricing data and cycle normalization. (marsh.com)
- Cross‑checked with P/E and P/B versus TRV and peers (CB, PGR, ALL). (companiesmarketcap.com)
If you’d like, I can share a compact spreadsheet of the residual‑income model so you can tweak ROE, retention, and discount rate assumptions and see how the per‑share value moves.